Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1918 in Hypertriglyceridemia (Phase III, China)
CTR20260142Phase 3Active
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1918 in hypertriglyceridemia, sponsored by Beijing Shengdi Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
SHR-1918
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20260142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260142.